HumaScan
This article was originally published in The Gray Sheet
Executive Summary
Donald Brounstein resigns as president and CEO of the Cranford, New Jersey firm May 19. Since founding the company in 1995, Brounstein managed the development and recent launch of the firm's Breast Alert breast cancer detection device ("The Gray Sheet" Nov. 17, In Brief). Elizabeth Tallett replaces Brounstein on an interim basis as chairman and acting CEO until a permanent replacement is found. Tallett maintains responsibilities as president and CEO of two start-up companies: Dioscor, a biotech management company and Ellard Pharmaceuticals...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.